Search Results - "SALLOWAY, S"

Aducanumab: Appropriate Use Recommendations by Cummings, Jeffrey, Aisen, P., Apostolova, L. G., Atri, A., Salloway, S., Weiner, M.

“…Aducanumab has been approved by the US Food and Drug Administration for treatment of Alzheimer’s disease (AD). Clinicians require guidance on the appropriate…”
Get full text

Clinical diagnosis of Alzheimer's disease: recommendations of the International Working Group by Dubois, Bruno, Villain, Nicolas, Frisoni, Giovanni B, Rabinovici, Gil D, Sabbagh, Marwan, Cappa, Stefano, Bejanin, Alexandre, Bombois, Stéphanie, Epelbaum, Stéphane, Teichmann, Marc, Habert, Marie-Odile, Nordberg, Agneta, Blennow, Kaj, Galasko, Douglas, Stern, Yaakov, Rowe, Christopher C, Salloway, Stephen, Schneider, Lon S, Cummings, Jeffrey L, Feldman, Howard H

“…In 2018, the US National Institute on Aging and the Alzheimer's Association proposed a purely biological definition of Alzheimer's disease that relies on…”
Get full text

Lecanemab: Appropriate Use Recommendations by Cummings, J., Apostolova, L., Rabinovici, G. D., Atri, A., Aisen, P., Greenberg, S., Hendrix, S., Selkoe, D., Weiner, M., Petersen, R. C., Salloway, S.

“…Lecanemab (Leqembi®) is approved in the United States for the treatment of Alzheimer’s disease (AD) to be initiated in early AD (mild cognitive impairment…”
Get full text

A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease by Salloway, S, Sperling, R, Gilman, S, Fox, N C, Blennow, K, Raskind, M, Sabbagh, M, Honig, L S, Doody, R, van Dyck, C H, Mulnard, R, Barakos, J, Gregg, K M, Liu, E, Lieberburg, I, Schenk, D, Black, R, Grundman, M

“…Bapineuzumab, a humanized anti-amyloid-beta (Abeta) monoclonal antibody for the potential treatment of Alzheimer disease (AD), was evaluated in a multiple…”
Get full text

A phase 2 randomized trial of ELND005, scyllo-inositol, in mild to moderate Alzheimer disease by SALLOWAY, S, SPERLING, R, CRANS, G, LIANG, E, QUINN, G, BAIRU, M, PASTRAK, A, CEDARBAUM, J. M, KEREN, R, PORSTEINSSON, A. P, VAN DYCK, C. H, TARIOT, P. N, GILMAN, S, ARNOLD, D, ABUSHAKRA, S, HERNANDEZ, C

“…This randomized, double-blind, placebo-controlled, dose-ranging phase 2 study explored safety, efficacy, and biomarker effects of ELND005 (an oral amyloid…”
Get full text

Aducanumab: Appropriate Use Recommendations Update by Cummings, Jeffrey, Rabinovici, G. D., Atri, A., Aisen, P., Apostolova, L. G., Hendrix, S., Sabbagh, M., Selkoe, D., Weiner, M., Salloway, S.

“…Aducanumab (Aduhelm) is approved in the United States for the treatment of patients with mild cognitive impairment due to Alzheimer’s disease or mild AD…”
Get full text

Deep brain stimulation of the ventral internal capsule ventral striatum for obsessive-compulsive disorder: worldwide experience by Greenberg, B D, Gabriels, L A, Malone, D A, Rezai, A R, Friehs, G M, Okun, M S, Shapira, N A, Foote, K D, Cosyns, P R, Kubu, C S, Malloy, P F, Salloway, S P, Giftakis, J E, Rise, M T, Machado, A G, Baker, K B, Stypulkowski, P H, Goodman, W K, Rasmussen, S A, Nuttin, B J

“…Psychiatric neurosurgery teams in the United States and Europe have studied deep brain stimulation (DBS) of the ventral anterior limb of the internal capsule…”
Get full text

Donepezil treatment of patients with MCI: A 48-week randomized, placebo-controlled trial by DOODY, R. S, FERRIS, S. H, SALLOWAY, S, SUN, Y, GOLDMAN, R, WATKINS, W. E, XU, Y, MURTHY, A. K

“…Treatment of mild cognitive impairment (MCI) with cholinesterase inhibitors may improve symptoms. In this multicenter, randomized, placebo-controlled trial,…”
Get full text

Efficacy of donepezil in mild cognitive impairment: A randomized placebo-controlled trial by SALLOWAY, S, FERRIS, S, KLUGER, A, GOLDMAN, R, GRIESING, T, KUMAR, D, RICHARDSON, S

“…To evaluate the efficacy and safety of the acetylcholinesterase inhibitor donepezil in a placebo-controlled trial in patients with mild cognitive impairment…”
Get full text

Gamma knife capsulotomy for intractable OCD: Neuroimage analysis of lesion size, location, and clinical response by McLaughlin, N. C. R., Magnotti, J. F., Banks, G. P., Nanda, P., Hoexter, M. Q., Lopes, A. C., Batistuzzo, M. C., Asaad, W. F., Stewart, C., Paulo, D., Noren, G., Greenberg, B. D., Malloy, P., Salloway, S., Correia, S., Pathak, Y., Sheehan, J., Marsland, R., Gorgulho, A., De Salles, A., Miguel, E. C., Rasmussen, S. A., Sheth, S. A.

“…Obsessive-compulsive disorder (OCD) affects 2–3% of the population. One-third of patients are poorly responsive to conventional therapies, and for a subgroup,…”
Get full text

Preclinical trials in autosomal dominant AD: Implementation of the DIAN-TU trial by Mills, S.M., Mallmann, J., Santacruz, A.M., Fuqua, A., Carril, M., Aisen, P.S., Althage, M.C., Belyew, S., Benzinger, T.L., Brooks, W.S., Buckles, V.D., Cairns, N.J., Clifford, D., Danek, A., Fagan, A.M., Farlow, M., Fox, N., Ghetti, B., Goate, A.M., Heinrichs, D., Hornbeck, R., Jack, C., Jucker, M., Klunk, W.E., Marcus, D.S., Martins, R.N., Masters, C.M., Mayeux, R., McDade, E., Morris, J.C., Oliver, A., Ringman, J.M., Rossor, M.N., Salloway, S., Schofield, P.R., Snider, J., Snyder, P., Sperling, R.A., Stewart, C., Thomas, R.G., Xiong, C., Bateman, R.J.

“…The Dominantly Inherited Alzheimer's Network Trials Unit (DIAN-TU) was formed to direct the design and management of interventional therapeutic trials of…”
Get full text

Galantamine treatment of vascular dementia : A randomized trial by AUCHUS, A. P, BRASHEAR, H. R, SALLOWAY, S, KORCZYN, A. D, DE DEYN, P. P, GASSMANN-MAYER, C

“…To evaluate efficacy and safety of galantamine for patients with vascular dementia (VaD). In this multinational, randomized, double-blind, placebo-controlled,…”
Get full text

MR imaging features of amyloid-related imaging abnormalities by Barakos, J, Sperling, R, Salloway, S, Jack, C, Gass, A, Fiebach, J B, Tampieri, D, Melançon, D, Miaux, Y, Rippon, G, Black, R, Lu, Y, Brashear, H R, Arrighi, H M, Morris, K A, Grundman, M

“…AD is one of the few leading causes of death without a disease-modifying drug; however, hopeful agents are in various phases of development. MR imaging…”
Get full text

The Future of Anti-Amyloid Trials by Aisen, P. S., Cummings, J., Doody, R., Kramer, L., Salloway, S., Selkoe, D. J., Sims, J., Sperling, R. A., Vellas, B.

“…The termination of many clinical trials of amyloid-targeting therapies for the treatment of Alzheimer’s disease (AD) has had a major impact on the AD clinical…”
Get full text

Initial Experiences with Amyloid-Related Imaging Abnormalities in Patients Receiving Aducanumab Following Accelerated Approval by Howe, Matthew D., Britton, K. J., Joyce, H. E., Pappas, G. J., Faust, M. A., Dawson, B. C., Riddle, M. C., Salloway, S. P.

“…Aducanumab is the first FDA-approved amyloid-lowering immunotherapy for Alzheimer’s disease. There is little real-world data to guide management of…”
Get full text

Plasma Biomarkers of AD Emerging as Essential Tools for Drug Development: An EU/US CTAD Task Force Report by Bateman, Randall J., Blennow, K., Doody, R., Hendrix, S., Lovestone, S., Salloway, S., Schindler, R., Weiner, M., Zetterberg, H., Aisen, P., Vellas, B.

“…There is an urgent need to develop reliable and sensitive blood-based biomarkers of Alzheimer’s disease (AD) that can be used for screening and to increase the…”
Get full text

The Effects of Subjective Cognitive Decline on APOE Genotype Disclosure in the Butler Hospital Alzheimer’s Prevention Registry by Lee, Athene K. W., Collier, M. K., Thompson, L. I., Popescu, D., Arthur, E., Correia, S., Salloway, S. P., Alber, J.

“…Background Subjective cognitive decline (SCD) and APOE genotyping are both instrumental in identifying high-risk individuals for Alzheimer’s disease (AD)…”
Get full text

Can We Use Blood Biomarkers as Entry Criteria and for Monitoring Drug Treatment Effects in Clinical Trials? A Report from the EU/US CTAD Task Force by Angioni, D., Hansson, O., Bateman, R. J., Rabe, C., Toloue, M., Braunstein, J. B., Agus, S., Sims, J. R., Bittner, T., Carrillo, M. C., Fillit, H., Masters, C. L., Salloway, S., Aisen, P., Weiner, M., Vellas, B., Gauthier, S., Abushakra, Susan, Afshar, Mohammad, Alam, John, Algeciras-Schimnich, Alicia, Andrieu, Sandrine, Ballard, Clive, Baruch, Amos, Batrla, Richard, Baudler, Monika, Bell, Joanne, Bozeat, Sasha, Brooks, Dawn, Brooks, Tricia, Bullain, Szofia, Burmeister, Jan, Cho, Min, Collins, Emily, Cook, Gavin, Cummings, Jeffrey, Dague, Chris, De Santi, Susan, Doody, Rachelle, Dunn, Billy, Egan, Michael, Eriksson, Sven, Esquivel, Rianne, Fagan, Tom, Ferrell, Phyllis, Gallagher, Michela, Grönblad, Anna-Kaija, Hains, Avis, Hampel, Harald, Hefting, Nanco, Hendrix, Suzanne, Ho, Carole, Hu, Helen, Ismail, Zahinoor, Jones, Daryl, Kinney, Gene, Kinnon, Paul, Kurzman, Ricky, Lannfelt, Lars, Lawson, John, LeBastard, Nathalie, Lewandowski, Nicole, Lim, Carine, Lyketsos, Costantine, Masterman, Donna, Lu, Ming, Mintun, Mark, Molinuevo, José Luis, Monteiro, Cecilia, Navia, Bradford, Odergren, Tomas, Osswald, Gunilla, Penny, Lewis, Pontecorvo, Michael, Porsteinsson, Anton, Raman, Rema, Respondek, Gesine, Reyderman, Larisa, Rogers, Sharon, Rosenberg, Paul, Rosenzweig-Lipson, Sharon, Roskey, Mark, Saad, Ziad, Schindler, Rachel, Selkoe, Dennis, Shulman, Melanie, Sink, Kaycee, Sipe, Lisa, Skovronsky, Daniel, Somers, Elizabeth, Soto, Maria, Streffer, Johannes, Such, Pedro, Suhy, Joyce, Touchon, Jacques, Vandijck, Manu, White, Anne, Wilson, David, Zago, Wagner, Zhou, Jin

“…In randomized clinical trials (RCTs) for Alzheimer’s Disease (AD), cerebrospinal fluid (CSF) and positron emission tomography (PET) biomarkers are currently…”
Get full text

Combination Therapy for Alzheimer’s Disease: Perspectives of the EU/US CTAD Task Force by Gauthier, Serge, Alam, J., Fillit, H., Iwatsubo, T., Liu-Seifert, H., Sabbagh, M., Salloway, S., Sampaio, C., Sims, J. R., Sperling, B., Sperling, R., Welsh-Bohmer, K. A., Touchon, J., Vellas, B., Aisen, P.

“…Combination therapy is expected to play an important role for the treatment of Alzheimer’s disease (AD). In October 2018, the European Union-North American…”
Get full text

Alzheimer’s Disease Clinical Trial Research Adaptation Following COVID-19 Pandemic Onset: National Sample of Alzheimer’s Clinical Trial Consortium Sites by Rhodus, Elizabeth K., Aisen, P., Grill, J. D., Rentz, D. M., Petersen, R. C., Sperling, R. A., Salloway, S. P., Pierce, D., Raman, R.

“…Background The COVID-19 pandemic created challenges in clinical research operations that required immediate and lasting changes. Ojbectives The purpose of this…”
Get full text